IDEAS home Printed from https://ideas.repec.org/a/bcp/journl/v9y2025i1p1485-1496.html

Effect of Market Entry on Generic Drug Prices: Medicare Data 2007-2022

Author

Listed:
  • Nguyen Xuan Nguyen

    (Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services)

  • Steven Sheingold

    (Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services)

  • Arielle Bosworth

    (Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services)

  • Rachael Zuckerman

    (Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services)

  • Thomas Buchmueller

    (Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services)

Abstract

Using the Medicare Part D drug event (PDE) data from 2007 to 2022, and both fixed effects or random effects at the drug level, we estimate the relationship of competitors and prices within each drug level while controlling for factors across drugs for 3 periods, 2007-11, 2012-15, and 2016-2019. We follow a drug 24 months and 36 months after first generic entry to examine whether the relationship between number of competitors and price would change over time. We find that in recent years new generic markets continue to be competitive. Drug prices fall with increasing number of generic competitors. Prices decline by 20% in markets with about 3 competitors. Prices continue to decline by 70% to 80% relative to the pre-generic entry price in markets of 10 or more competitors following 3 years after first generic entry. We also find that the impact of competition on relative prices are similar for generic drugs first entering the market in the most recent period 2016-2019 to the earlier periods, 2007-11 or 2012-15.

Suggested Citation

  • Nguyen Xuan Nguyen & Steven Sheingold & Arielle Bosworth & Rachael Zuckerman & Thomas Buchmueller, 2025. "Effect of Market Entry on Generic Drug Prices: Medicare Data 2007-2022," International Journal of Research and Innovation in Social Science, International Journal of Research and Innovation in Social Science (IJRISS), vol. 9(1), pages 1485-1496, January.
    • Handle: RePEc:bcp:journl:v:9:y:2025:i:1:p:1485-1496
    as

    Download full text from publisher

    File URL: https://www.rsisinternational.org/journals/ijriss/Digital-Library/volume-9-issue-1/1485-1496.pdf
    Download Restriction: no
    File URL: https://rsisinternational.org/journals/ijriss/articles/effect-of-market-entry-on-generic-drug-prices-medicare-data-2007-2022/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Ernst R. Berndt & Joseph P. Newhouse, 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," NBER Working Papers 16297, National Bureau of Economic Research, Inc.
    2. Steven N. Wiggins & Robert Maness, 2004. "Price Competition in Pharmaceuticals: The Case of Anti-infectives," Economic Inquiry, Western Economic Association International, vol. 42(2), pages 247-263, April.
    3. Rena M. Conti & Ernst R. Berndt, 2020. "Four Facts Concerning Competition in US Generic Prescription Drug Markets," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 27(1), pages 27-48, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nguyen Xuan Nguyen & Steven H. Sheingold & Wafa Tarazi & Arielle Bosworth, 2022. "Effect of Competition on Generic Drug Prices," Applied Health Economics and Health Policy, Springer, vol. 20(2), pages 243-253, March.
    2. Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
    3. Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
    4. Raymond J. March & Adam G. Martin & Audrey Redford, 2016. "The substance of entrepreneurship and the entrepreneurship of substances," Journal of Entrepreneurship and Public Policy, Emerald Group Publishing Limited, vol. 5(2), pages 201-220, August.
    5. Nicholas Apergis & Vasilios Monastiriotis, 2013. "Price Concentration: New Evidence from Greek Industries and the Cournot Model," Economic Papers, The Economic Society of Australia, vol. 32(2), pages 265-271, June.
    6. Leslie Wilson & Fatema Turkistani & Dang M. Tran & Wei Huang & Tracy Kuo Lin, 2019. "Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers’ Compensation System," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 231-242, April.
    7. Wang, Lucy Xiaolu & Zahur, Nahim Bin, 2025. "Procurement institutions and essential drug supply in low and middle-income countries," Journal of Health Economics, Elsevier, vol. 101(C).
    8. Suppliet, Moritz & Herr, Annika, 2016. "Cost-Sharing and Drug Pricing Strategies : Introducing Tiered Co-Payments in Reference Price Markets," Other publications TiSEM 4d692f0e-8577-4392-b413-2, Tilburg University, School of Economics and Management.
    9. Lin Lin & Bo Wang, 2025. "Marketing Status and Brand‐Name Drug Prices: Evidence From Rx‐To‐OTC Switch," Health Economics, John Wiley & Sons, Ltd., vol. 34(6), pages 1064-1084, June.
    10. Bergman, Mats & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," HUI Working Papers 116, HUI Research.
    11. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    12. Laura Birg, 2023. "Pharmaceutical regulation under market integration through parallel trade," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 56(4), pages 1322-1346, November.
    13. John Rizzo & Richard Zeckhauser, 2009. "Generic script share and the price of brand-name drugs: the role of consumer choice," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 291-316, September.
    14. Michael Salinger & Pauline Ippolito & Joel Schrag, 2007. "Economics at the FTC: Pharmaceutical Patent Dispute Settlements and Behavioral Economics," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(2), pages 85-105, September.
    15. Herr, A. & Suppliet, M., 2011. "Co-Payment Exemptions and Reference Prices: an Empirical Study of Pharmaceutical Prices in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 11/18, HEDG, c/o Department of Economics, University of York.
    16. Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016. "Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry," RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
    17. Luke M. Olson & Brett W. Wendling, 2018. "Estimating the Causal Effect of Entry on Generic Drug Prices Using Hatch–Waxman Exclusivity," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 53(1), pages 139-172, August.
    18. Andia, Tatiana & Mantilla, César & Morales, Álvaro & Ortiz, Santiago & Rodríguez-Lesmes, Paul, 2022. "Does price-cap regulation work for increasing access to contraceptives? Aggregate- and pharmacy-level evidence from Colombia," Social Science & Medicine, Elsevier, vol. 311(C).
    19. Puig-Junoy, Jaume & López-Valcárcel, Beatriz González, 2014. "Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market, 1995–2007," Health Policy, Elsevier, vol. 116(2), pages 170-181.
    20. Bokhari, Farasat A.S. & Mariuzzo, Franco, 2018. "Demand estimation and merger simulations for drugs: Logits v. AIDS," International Journal of Industrial Organization, Elsevier, vol. 61(C), pages 653-685.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bcp:journl:v:9:y:2025:i:1:p:1485-1496. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Dr. Pawan Verma (email available below). General contact details of provider: https://rsisinternational.org/journals/ijriss/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.